 Vienna Brunt
Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vasodilation | 17 | 2025 | 499 | 2.760 |
Why?
| | Hyperthermia, Induced | 5 | 2021 | 116 | 2.300 |
Why?
| | Vascular Stiffness | 8 | 2025 | 494 | 2.090 |
Why?
| | Hot Temperature | 12 | 2021 | 391 | 2.020 |
Why?
| | Methylamines | 5 | 2022 | 34 | 1.870 |
Why?
| | Endothelium, Vascular | 10 | 2025 | 927 | 1.860 |
Why?
| | Aging | 12 | 2024 | 1864 | 1.860 |
Why?
| | Gastrointestinal Microbiome | 5 | 2024 | 697 | 1.820 |
Why?
| | Skin | 9 | 2017 | 752 | 1.510 |
Why?
| | Vascular Diseases | 3 | 2023 | 243 | 1.450 |
Why?
| | Drinking Water | 2 | 2022 | 84 | 1.420 |
Why?
| | Nitric Oxide | 10 | 2025 | 915 | 1.270 |
Why?
| | Cardiovascular Diseases | 6 | 2025 | 2111 | 1.200 |
Why?
| | Aorta | 5 | 2025 | 417 | 1.010 |
Why?
| | Microcirculation | 4 | 2017 | 149 | 1.000 |
Why?
| | Progesterone | 4 | 2025 | 254 | 0.970 |
Why?
| | Potassium Channels, Calcium-Activated | 3 | 2016 | 11 | 0.940 |
Why?
| | Hyperemia | 4 | 2014 | 49 | 0.940 |
Why?
| | Acetylcholine | 5 | 2022 | 185 | 0.930 |
Why?
| | Brachial Artery | 5 | 2021 | 205 | 0.910 |
Why?
| | Oxidative Stress | 3 | 2021 | 1317 | 0.900 |
Why?
| | Carotid Arteries | 6 | 2024 | 206 | 0.860 |
Why?
| | Estradiol | 4 | 2025 | 521 | 0.850 |
Why?
| | Blood Pressure | 7 | 2025 | 1786 | 0.780 |
Why?
| | Lyases | 1 | 2022 | 12 | 0.780 |
Why?
| | Femoral Artery | 2 | 2020 | 179 | 0.730 |
Why?
| | Steam Bath | 1 | 2021 | 1 | 0.720 |
Why?
| | Hydrotherapy | 1 | 2021 | 8 | 0.720 |
Why?
| | Immersion | 2 | 2021 | 8 | 0.710 |
Why?
| | Skin Physiological Phenomena | 4 | 2017 | 25 | 0.700 |
Why?
| | Blood Flow Velocity | 5 | 2021 | 413 | 0.660 |
Why?
| | Cardiovascular System | 2 | 2021 | 137 | 0.660 |
Why?
| | Pulse Wave Analysis | 6 | 2025 | 272 | 0.660 |
Why?
| | Satellite Cells, Skeletal Muscle | 1 | 2020 | 29 | 0.630 |
Why?
| | Baroreflex | 2 | 2025 | 57 | 0.630 |
Why?
| | Frailty | 1 | 2022 | 170 | 0.620 |
Why?
| | Sarcopenia | 1 | 2020 | 83 | 0.590 |
Why?
| | Vasodilator Agents | 5 | 2024 | 331 | 0.540 |
Why?
| | Mice, Inbred C57BL | 9 | 2025 | 5757 | 0.530 |
Why?
| | Myocardial Ischemia | 1 | 2018 | 263 | 0.520 |
Why?
| | Biological Factors | 2 | 2013 | 39 | 0.490 |
Why?
| | Acclimatization | 1 | 2017 | 177 | 0.480 |
Why?
| | Arteries | 4 | 2024 | 269 | 0.460 |
Why?
| | Young Adult | 16 | 2025 | 13209 | 0.450 |
Why?
| | Skin Temperature | 2 | 2012 | 30 | 0.450 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2022 | 2189 | 0.440 |
Why?
| | Cellular Senescence | 3 | 2025 | 189 | 0.440 |
Why?
| | Reperfusion Injury | 1 | 2016 | 279 | 0.430 |
Why?
| | Heart | 2 | 2018 | 655 | 0.420 |
Why?
| | Peripheral Arterial Disease | 1 | 2020 | 475 | 0.420 |
Why?
| | Mice | 13 | 2025 | 17787 | 0.420 |
Why?
| | Pressoreceptors | 1 | 2013 | 19 | 0.420 |
Why?
| | Hemodynamics | 2 | 2021 | 1113 | 0.410 |
Why?
| | Vasomotor System | 1 | 2013 | 47 | 0.410 |
Why?
| | Eicosanoids | 1 | 2012 | 62 | 0.370 |
Why?
| | Animals | 17 | 2025 | 36940 | 0.360 |
Why?
| | Doxorubicin | 2 | 2025 | 362 | 0.360 |
Why?
| | Humans | 35 | 2025 | 137585 | 0.350 |
Why?
| | Xanthine Oxidase | 1 | 2011 | 81 | 0.350 |
Why?
| | Progestins | 1 | 2011 | 79 | 0.350 |
Why?
| | Superoxides | 2 | 2022 | 202 | 0.350 |
Why?
| | NADPH Oxidases | 1 | 2011 | 113 | 0.350 |
Why?
| | Angiotensin II | 1 | 2011 | 99 | 0.340 |
Why?
| | Reactive Oxygen Species | 2 | 2021 | 622 | 0.320 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2024 | 2531 | 0.320 |
Why?
| | Heating | 3 | 2017 | 23 | 0.300 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1809 | 0.290 |
Why?
| | Estrogens | 1 | 2011 | 367 | 0.290 |
Why?
| | Cyclic N-Oxides | 2 | 2020 | 29 | 0.280 |
Why?
| | Inflammation | 4 | 2023 | 2837 | 0.270 |
Why?
| | Interleukin-1 | 2 | 2022 | 965 | 0.260 |
Why?
| | Male | 21 | 2025 | 67762 | 0.260 |
Why?
| | Forearm | 2 | 2017 | 119 | 0.250 |
Why?
| | NG-Nitroarginine Methyl Ester | 4 | 2014 | 48 | 0.250 |
Why?
| | Female | 21 | 2025 | 73304 | 0.250 |
Why?
| | Heart Rate | 3 | 2025 | 822 | 0.230 |
Why?
| | Vagus Nerve | 1 | 2025 | 86 | 0.230 |
Why?
| | Age Factors | 4 | 2024 | 3295 | 0.230 |
Why?
| | Premenopause | 1 | 2025 | 131 | 0.230 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2025 | 127 | 0.230 |
Why?
| | Bottle-Nosed Dolphin | 1 | 2024 | 4 | 0.230 |
Why?
| | Glucose | 2 | 2020 | 1020 | 0.220 |
Why?
| | Adult | 14 | 2025 | 37929 | 0.220 |
Why?
| | Endothelial Cells | 2 | 2020 | 785 | 0.220 |
Why?
| | Flavonols | 1 | 2023 | 18 | 0.210 |
Why?
| | Antioxidants | 2 | 2020 | 584 | 0.210 |
Why?
| | Regional Blood Flow | 5 | 2021 | 474 | 0.210 |
Why?
| | Tetraethylammonium | 2 | 2013 | 16 | 0.200 |
Why?
| | Butanols | 1 | 2022 | 8 | 0.200 |
Why?
| | Spin Labels | 2 | 2020 | 48 | 0.190 |
Why?
| | Sugars | 1 | 2022 | 41 | 0.190 |
Why?
| | Nitric Oxide Synthase | 2 | 2013 | 240 | 0.190 |
Why?
| | Diet, Western | 1 | 2022 | 81 | 0.190 |
Why?
| | Ultrasonography, Doppler | 3 | 2021 | 124 | 0.190 |
Why?
| | Spirostans | 1 | 2021 | 4 | 0.180 |
Why?
| | Carotid Artery, Common | 1 | 2021 | 36 | 0.180 |
Why?
| | Feces | 1 | 2024 | 484 | 0.170 |
Why?
| | Interleukins | 1 | 2022 | 250 | 0.170 |
Why?
| | Reflex | 1 | 2020 | 68 | 0.170 |
Why?
| | Middle Aged | 6 | 2024 | 33479 | 0.160 |
Why?
| | Dietary Supplements | 2 | 2023 | 561 | 0.160 |
Why?
| | C-Reactive Protein | 1 | 2022 | 410 | 0.160 |
Why?
| | Microdialysis | 3 | 2014 | 52 | 0.160 |
Why?
| | Aged | 5 | 2024 | 23961 | 0.160 |
Why?
| | Tyrosine | 1 | 2020 | 222 | 0.160 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2020 | 204 | 0.160 |
Why?
| | Ascorbic Acid | 1 | 2020 | 177 | 0.150 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 2 | 2016 | 77 | 0.150 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2025 | 617 | 0.150 |
Why?
| | Metabolomics | 1 | 2024 | 678 | 0.150 |
Why?
| | Heme Oxygenase-1 | 1 | 2018 | 64 | 0.150 |
Why?
| | Transcription Factor RelA | 1 | 2018 | 87 | 0.140 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2018 | 107 | 0.140 |
Why?
| | Exercise Tolerance | 1 | 2019 | 279 | 0.140 |
Why?
| | Muscle Contraction | 1 | 2020 | 424 | 0.140 |
Why?
| | Extracellular Matrix | 1 | 2021 | 528 | 0.130 |
Why?
| | Laser-Doppler Flowmetry | 2 | 2013 | 32 | 0.130 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2019 | 177 | 0.130 |
Why?
| | Shear Strength | 1 | 2016 | 67 | 0.130 |
Why?
| | Arterial Pressure | 2 | 2017 | 126 | 0.130 |
Why?
| | Adolescent | 5 | 2021 | 21513 | 0.130 |
Why?
| | Hypertension | 1 | 2025 | 1295 | 0.120 |
Why?
| | Heat-Shock Response | 1 | 2016 | 77 | 0.120 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2016 | 90 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1242 | 0.120 |
Why?
| | Smoking | 2 | 2014 | 1627 | 0.120 |
Why?
| | Vascular Resistance | 1 | 2016 | 375 | 0.120 |
Why?
| | Healthy Volunteers | 1 | 2015 | 199 | 0.110 |
Why?
| | Time Factors | 3 | 2021 | 6828 | 0.110 |
Why?
| | Interleukin-6 | 1 | 2018 | 778 | 0.110 |
Why?
| | Stroke Volume | 1 | 2017 | 612 | 0.110 |
Why?
| | Transdermal Patch | 1 | 2013 | 15 | 0.100 |
Why?
| | Hormone Antagonists | 1 | 2013 | 34 | 0.100 |
Why?
| | Microvessels | 1 | 2014 | 88 | 0.100 |
Why?
| | Administration, Cutaneous | 1 | 2013 | 129 | 0.100 |
Why?
| | Adaptation, Physiological | 1 | 2017 | 553 | 0.100 |
Why?
| | Prostaglandins | 1 | 2013 | 97 | 0.100 |
Why?
| | Sulfaphenazole | 1 | 2012 | 3 | 0.100 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2012 | 20 | 0.100 |
Why?
| | Sex Factors | 2 | 2021 | 2071 | 0.100 |
Why?
| | Cognition | 1 | 2020 | 1153 | 0.100 |
Why?
| | Potassium Channel Blockers | 1 | 2012 | 37 | 0.100 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 48 | 0.090 |
Why?
| | Cell Differentiation | 1 | 2020 | 1991 | 0.090 |
Why?
| | Enzyme Inhibitors | 2 | 2013 | 840 | 0.090 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2013 | 212 | 0.090 |
Why?
| | Rats | 1 | 2020 | 5647 | 0.090 |
Why?
| | Estrogen Antagonists | 1 | 2011 | 45 | 0.090 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 786 | 0.090 |
Why?
| | Administration, Oral | 1 | 2013 | 816 | 0.090 |
Why?
| | Linear Models | 1 | 2013 | 849 | 0.090 |
Why?
| | Cells, Cultured | 1 | 2018 | 4193 | 0.090 |
Why?
| | Analysis of Variance | 1 | 2013 | 1316 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 2129 | 0.080 |
Why?
| | Obesity | 1 | 2019 | 2992 | 0.060 |
Why?
| | Nitroprusside | 1 | 2025 | 69 | 0.060 |
Why?
| | Aniline Compounds | 1 | 2025 | 102 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2016 | 10811 | 0.060 |
Why?
| | Healthy Aging | 1 | 2024 | 35 | 0.050 |
Why?
| | Elastic Modulus | 1 | 2024 | 123 | 0.050 |
Why?
| | Models, Animal | 1 | 2024 | 384 | 0.050 |
Why?
| | Sulfonamides | 1 | 2025 | 513 | 0.050 |
Why?
| | Elastin | 1 | 2021 | 78 | 0.040 |
Why?
| | Collagen | 1 | 2021 | 452 | 0.040 |
Why?
| | Sympathetic Nervous System | 1 | 2019 | 182 | 0.040 |
Why?
| | Congresses as Topic | 1 | 2018 | 233 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2025 | 4295 | 0.030 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2017 | 382 | 0.030 |
Why?
| | Skin Aging | 1 | 2013 | 20 | 0.030 |
Why?
| | Ketorolac | 1 | 2013 | 20 | 0.020 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2013 | 79 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 2057 | 0.020 |
Why?
| | Electrocardiography | 1 | 2011 | 629 | 0.020 |
Why?
| | Exercise | 1 | 2017 | 2057 | 0.010 |
Why?
| | Risk Factors | 1 | 2019 | 10388 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2011 | 5131 | 0.010 |
Why?
|
|
Brunt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|